Home Current Issue Previous Issues Published Ahead-of-Print Collections For Authors Journal Info
Skip Navigation LinksHome > October 11, 1997 - Volume 11 - Issue 12 > Impact of protease inhibitors on AIDS‐defining events and ho...
AIDS:
Fast Track

Impact of protease inhibitors on AIDS‐defining events and hospitalizations in 10 French AIDS reference centres

Mouton, Yves1,11; Alfandari, Serge1; Valette, Michel1; Cartier, François2; Dellamonica, Pierre3; Humbert, Guy4; Lang, Jean Marie5; Massip, Patrice6; Mechali, Denis7; Leclercq, Pascale8; Modai, Jacques9; Portier, Henri10; Fédération Nationale des Centres de Lutte contre le SIDA

Collapse Box

Abstract

Objective: To assess the clinical and economic consequences of the use of protease inhibitors in the treatment of HIV infection.

Design: Multicentric, observational, retrospective cohort study.

Setting: Ten AIDS reference centres in France.

Patients: All patients followed in each centre from September 1995 through October 1996.

Main outcome measures: AIDS-defining events, death, health-care resources use, administration of antiretroviral therapy.

Results: Data from 7749 patients in 10 centres showed a drop in hospitalization days by 35%, new AIDS cases by 35%, and deaths by 46%. In the same period, the proportion of patients receiving antiretrovirals rose from 36 to 53% including highly active antiretroviral therapy (HAART), which rose from 0.3 to 18%. Overall cost evaluation showed a slight increase of monthly treatment cost of US$ 12 per patient. Comparison of the three centres that used HAART earliest to the three centres that used it latest showed a clear benefit to early HAART with a drop in hospitalization days by 41%, new AIDS cases by 41% and deaths by 69%. The proportion of patients with HAART rose to 27% and monthly health-care cost decreased by US$ 248 852 (i.e., by US$ 101 per patient per month). Late prescribing centres experienced a less marked effect with a drop in hospitalization days by 22%, new AIDS cases by 31%, and deaths by 32.5%. Proportion of patients with HAART rose to 12% and monthly health-care costs increased by US$ 113 578 (i.e., by US$ 38 per patient per month).

Conclusions: This study supports the extensive use of HAART in HIV-infected patients.

© Lippincott-Raven Publishers.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.